{
    "organizations": [],
    "uuid": "d1ab3793a4aee6a497c1399a9be2903871abb09a",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/20/globe-newswire-altimmune-to-announce-year-end-2017-financial-results-on-march-29.html",
    "ord_in_thread": 0,
    "title": "Altimmune to Announce Year End 2017 Financial Results on March 29",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.\nConference Call Details Date: Thursday, March 29 Time: 8:30am Eastern Time Domestic: 866-548-4713 International: 323-794-2093 Conference ID: 6280732 Webcast: http://public.viavid.com/index.php?id=128569 Replays, Available through April 12th: Domestic: 844-512-2921 International: 412-317-6671 Replay PIN: 6280732 About Altimmune\nAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.\nContacts:\nBill Enright\nPresident and CEO\nPhone: 240-654-1450\nenright@altimmune.com\nAshley Robinson\nLifeSci Advisors, LLC\n617-535-7742\narr@lifesciadvisors.com\nSource:Altimmune, Inc.",
    "published": "2018-03-20T23:01:00.000+02:00",
    "crawled": "2018-03-20T22:25:12.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "gaithersburg",
        "march",
        "globe",
        "newswire",
        "altimmune",
        "nasdaq",
        "alt",
        "immunotherapeutics",
        "company",
        "today",
        "announced",
        "announce",
        "financial",
        "result",
        "quarter",
        "year",
        "ended",
        "december",
        "market",
        "open",
        "host",
        "conference",
        "call",
        "thursday",
        "march",
        "conference",
        "call",
        "detail",
        "date",
        "thursday",
        "march",
        "time",
        "eastern",
        "time",
        "domestic",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "replay",
        "available",
        "april",
        "12th",
        "domestic",
        "international",
        "replay",
        "pin",
        "altimmune",
        "altimmune",
        "immunotherapeutics",
        "company",
        "focused",
        "development",
        "product",
        "stimulate",
        "robust",
        "durable",
        "immune",
        "response",
        "prevention",
        "treatment",
        "disease",
        "including",
        "nasovax",
        "phase",
        "seasonal",
        "influenza",
        "vaccine",
        "candidate",
        "heptcell",
        "phase",
        "immunotherapeutic",
        "candidate",
        "potential",
        "cure",
        "chronic",
        "hepatitis",
        "company",
        "also",
        "two",
        "united",
        "state",
        "government",
        "funded",
        "anthrax",
        "vaccine",
        "candidate",
        "intended",
        "improve",
        "protection",
        "safety",
        "favorable",
        "dosage",
        "storage",
        "requirement",
        "compared",
        "anthrax",
        "vaccine",
        "contact",
        "bill",
        "enright",
        "president",
        "ceo",
        "phone",
        "enright",
        "ashley",
        "robinson",
        "lifesci",
        "advisor",
        "llc",
        "arr",
        "source",
        "altimmune",
        "inc"
    ]
}